
Heidi Joy Gray MD
Gynecologic Oncology
Professor and Chief, Division of Gyn Oncology, Obstetrics & Gynecology, University of Washington School of Medicine
Join to view full profile
1959 Ne Pacific StSeattle, WA 98195
Phone+1 206-598-8300
Fax+1 206-598-3590
Dr. Gray is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Gynecologic Oncology, 2001 - 2004
University of WashingtonResidency, Obstetrics and Gynecology, 1997 - 2001
David Geffen School of Medicine at UCLAClass of 1997
Certifications & Licensure
WA State Medical License 1999 - 2027
PA State Medical License 2001 - 2004
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
- Ovarian Cancer Vaccine for Patients in Remission
- Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms Start of enrollment: 2012 Sep 12
Publications & Presentations
PubMed
- 5 citationsGynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access.Ann Oluloro, Elizabeth M Swisher, Heidi J Gray, Barbara Goff, Kemi M Doll
Journal of the National Cancer Institute. 2025-05-01 - 120 citationsNCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.Joyce Liu, Andrew Berchuck, Floor J Backes, Joshua Cohen, Rachel Grisham
Journal of the National Comprehensive Cancer Network. 2024-10-01 - 13 citationsNRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma.Tracy T Batchelor, Minhee Won, Arnab Chakravarti, Costas G Hadjipanayis, Wenyin Shi
Neuro-Oncology Advances. 2023-10-11
Other
- Adjuvant treatment of intermediate-risk endometrial cancerGray HJ, Koh W
http://www.uptodate.com/contents/adjuvant-treatment-of-intermediate-risk-endometrial-cancer
UpToDate, Wolters Kluwer Health - 2012-08-14
Press Mentions
PARIS® Test Identified Effective Therapy for Patient with Terminal Ovarian CancerSeptember 13th, 2021
SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS® Test in Ovarian CancerApril 13th, 2021
SGO 2019: Despite Missed Endpoint, JAVELIN Trial PD-L1 Subgroup Analysis RedeemsMarch 19th, 2019
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: